International conference “Life Sciences Baltics 2012” takes place in Vilnius, Lithuania from 12 until 14 September, where, besides other leading pharmaceutical specialists, Chairman of the Board of Grindeks Juris Bundulis is also participating. Today, on 13 September he delivered presentation, where conference participants were introduced to success, business model and operational principles of Grindeks.
Within the participants of the conference “Life Sciences Baltics 2012” there are significant specialists, including Nobel Prize laureate, world-class experts, prominent business people and high-level public officials. The conference provides an opportunity for all exhibitors and visitors to meet the winning mix of industry players, including associated manufacturers and service providers operating in the Baltic countries. The purpose of the conference “Life Sciences Baltics 2012” is to gather all of the leading pharmaceutical players in the Baltic States, which also includes Grindeks.
In his presentation Chairman of the Board of Grindeks Juris Bundulis also informed about the investments, financial data and success factors, emphasizing company’s modern infrastructure, world-class facilities and their capacity. Juris Bundulis also introduced products, services and worldwide positions of Grindeks to the participants of the conference.
Chairman of the Board of Grindeks Juris Bundulis: “We believe in our ideas and dare to take risks for the achievement of our highly determined goals. Grindeks has proven that it is a significant player of pharmaceutical industry in the Baltic States, as well as elsewhere in the world, therefore we are pleased to participate in this conference alongside other leaders of the industry. The main task of the company is discovering patient and client expectations and creating according supplies. We always think a step ahead and never doubt our ideas and abilities, which is the basis of our success.”
To find out more about the conference: http://www.lsb2012.com
Grindeks is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. The Group of Grindeks consists of four subsidiary companies in Latvia, Estonia and Russia, as well representative offices in ten countries.
Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein. Currently Grindeks produces 22 active pharmaceutical ingredients.
Products of the company are exported to 50 countries and its export comprises more than 95% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, Germany and the Netherlands. In 2010 The Ministry of Economics of Republic of Latvia and Investment and Development Agency of Latvia awarded Grindeks as the most export potential company of Latvia.
During the last years the company realized many considerable investment projects in purpose to increase production capacity and develop infrastructure and invested 32.7 million lats within five years.
JSC Grindeks shares are listed in the Official List of „Nasdaq OMX Riga”. Major shareholders of JSC Grindeks are Kirovs Lipmans –33.29%, Anna Lipmane – 16.69%, “AB.LV Private Equity fund 2010” – 11.38%, “Skandinaviska Enskilda Banken” (nominal holder) – 10.53%, “Swedbank” AS Clients Account (nominal holder) – 8.79%.
More information about the company – www.grindeks.lv/en/
Head of the Communications Department, JSC Grindeks
Phones: (+371) 67083370, (+371) 29256012
Fax: (+371) 67083505